A panel of advisers to the US Centers for Disease Control and Prevention (CDC) on Thursday unanimously backed COVID-19 vaccine boosters for recipients of the Moderna Inc and Johnson & Johnson shots, and said Americans can choose a different shot from their original inoculation as a booster.
If the recommendations are accepted by the CDC’s director,who could sign off on the guidance as early as later on Thursday, the agency will align with the US Food and Drug Administration’s authorisation US FDA clears Moderna, J&J COVID-19 boosters, backs use of different vaccine for boost on Wednesday for the additional boosters and “mix-and-match”dosing.
That could pave the way for the extra shots to become available immediately afterward to millions of Americans.
Still, health officials and public health experts said the booster rollout could be confusing.
The panel struggled with trying to make the language of its recommendations as clear as possible, and also offer flexibility for patients to get a vaccine of their choice.
“A really important aspect of all of this is being clear and not dancing on the head of a pin, so that we don’t further confuse the American people,” said Dr. Beth Bell, a panel member and clinical professor in the department of global health at the University of Washington in Seattle.
The recommendations also open the door for recipients of the one-shot J&J vaccine to get a dose of the Pfizer or Moderna vaccines that have been shown to afford greater protection in a variety of studies.
Although these vaccines have been highly effective in preventing serious illness and death, some government scientists have suggested that boosters are needed to keep immunity high, especially as the extremely contagious Delta variant of the virus can cause breakthrough infections among some who are fully vaccinated.
ACIP voted to recommend booster doses for everyone 18 and older who received a first dose of Johnson & Johnson’s vaccine at least two months earlier.
For those who received their second dose of Moderna’s vaccine at least six months earlier, ACIP recommended a third shot for those age 65 and over, as well as some individuals at risk or severe illness and those at high risk of exposure to the virus through their jobs.
Dr. Helen Talbot, an infectious disease expert at Vanderbilt University and a panel member, said she voted for the recommendation, but cautioned, “Moderna has very good vaccine efficacy. There will be some confusion with the higher versus lower dose.”
Booster doses of the Moderna vaccine will be 50 micrograms, half the strength of the original shots.
“Those not at high risk should be really thoughtful about getting the higher dose. I do think we need to be very aware of potential complications.”
Experts said communicating those risks could be an issue,especially given the flexibility of allowing people to choose a different vaccine from their original series.
“At the end of the day, even that phrase ‘mix and match ‘ pretty much gives people the latitude to … do pretty much anything,” Glen Nowak, a risk communication professor at the University of Georgia and former communications director for CDC’s National Immunisation Programme said after the meeting. “I think that’s going to be an issue.”
The FDA and CDC previously signed off on booster shots of the COVID-19 vaccine from Pfizer Inc and partner BioNTech SE for the same groups included in the Moderna recommendations.
Pfizer released data on Thursday suggesting that a booster dose was highly protective for those age 16 and older compared with protection nearly a year after receiving the two-dose regimen due to waning efficacy over time.
About 11.6 million people have so far received a booster dose, according to data from the CDC.
The FDA and CDC have been under pressure to authorize the additional shots after the White House announced plans in August for a widespread booster campaign.
Other countries such as Israel have begun offering boosters to a broad population, but it is not yet known whether the United States will follow suit.